Gale Dunham, a pharmacist in Calistoga, Calif., knows the devastation the opioid epidemic has wrought, and she is glad the anti-overdose drug naloxone is becoming more accessible.
But so far, Dunham said, she has not taken advantage of a California law that allows pharmacists to dispense the medication to patients without a doctor’s prescription. She said she plans to take the training required at some point but has not yet seen much demand for the drug.
Conservative groups are pushing President Trump to make ObamaCare repeal a priority in 2018, even as some Republicans signal a desire to move on from the issue.
A letter to Trump signed by 43 right-leaning groups calls for health-care reform to be the focus of the fast-track process known as reconciliation this year. Using that process would allow Republicans to repeal ObamaCare in the Senate without Democratic votes, but it would also preclude them from using the tool for other priorities like welfare reform.
The CMS has proposed tweaking the way it pays Medicare Advantage health plans starting in 2019 by accounting for beneficiaries’ mental health, substance abuse disorder and chronic kidney disease conditions in the risk-adjustment model.Under the proposed changes, risk scores would reflect the total number of conditions for an individual beneficiary, in addition to viewing conditions individually. By taking into account the number of conditions a beneficiary has among the conditions that are included in the Medicare Advantage payment model, the CMS said plans’ risk scores are projected to increase by 1.1%.
When Walgreens Boots Alliance reports earnings this week, it will include results from its now year-old relationship with a pharmacy benefit manager (PBM) owned by many of the nation’s largest Blue Cross and Blue Shield companies.
Walgreens’ partnership with Prime Therapeutics is one of the reasons CVS Health needed to buy Aetna so Walgreens doesn’t feel the need to respond with a health plan purchase of its own. The Prime deal is also a reason the nation’s largest drugstore chain has rebuffed the idea of owning a PBM.
Prime is owned by 18 Blue Cross and Blue Shield plans with more than 20 million health plan members across the country. As part of the Prime-Walgreens relationship, these Blue Cross members are in effect directed away from CVS drugstores to Walgreens pharmacies as part of Prime’s national preferred pharmacy network. The preferred pharmacy network began Jan. 1, 2017.
California officials are bracing for healthcare battles in Washington to have a major impact on the state’s budget and programs. Activists and politicians are planning a showdown over whether or not to establish a single-payer healthcare system in the state. And prescription drug manufacturers are the target of a number of bills meant to target the rising costs of medication.
Sound familiar? Turns out the brewing healthcare battles in California in 2018 aren’t all that different from those from 2017.
“I made myself a hypodermic injection of a triple dose of morphia and sank down on the couch in my consulting-room….I told her I was all right, all I wanted was twenty-four hours’ sleep, she was not to disturb me unless the house was on fire.” – Axel Munthe, MD, The Story of San Michele (1929)
When people in this country mention the opioid epidemic, most of the time it is in the context of addiction with its ensuing criminality and social deprivation, and the focus is on opioids’ medical complications like withdrawal, overdose and death.
Black and Hispanic preterm infants in New York were more likely to be born in poor quality-of-care facilities, which contributed to higher morbidity and mortality rates among these populations, according to a new study.Neonatal intensive-care units across New York have wide variations in quality of care, according to the study published Tuesday in JAMA Pediatrics, and that variation can affect patient outcomes.At the worst of the 39 New York hospitals studied for the period of 2010-2014, infants died or developed chronic diseases at a rate eight times higher than the best hospitals; 43.4% of black and 34.4% of Hispanic preterm infants were born in the hospitals with the highest rates of neonatal morbidity and mortality.
Price transparency and sales funnels—what do these have in common? Keep reading and it’ll all make sense. I’ve repeatedly mentioned the importance of price transparency on this blog. And not just price transparency but using price transparency as a lead-generation tool for your medical practice. In other words, how to attract patients so you can capture their contact info (a lead). Now, let me explain how your medical practice fits the sales funnel paradigm just like any business-to-consumer business out there.
When a hepatitis C treatment called Harvoni was released in 2014, Dr. Ronald Cirillo knew it was big.
“It’s the reason that dragged me out of retirement!” he says.
Cirillo specialized in treating hepatitis C for more than 30 years in Stamford, Conn., before retiring to Bradenton, Fla. During his time in Connecticut, the only available treatment for hepatitis C had terrible side effects and it didn’t work very well. It cured the viral infection less than half the time. But the newer drugs Harvoni and Solvaldi cure almost everybody, with few adverse reactions.
Major depressive disorder — the persistent, intense sadness that most people know simply as depression — is pervasive: One estimate pegs 7 percent of Americans over 18 as having had an episode.
The condition typically is treated with antidepressants as well as psychotherapy and lifestyle changes, since alcohol or drug abuse, medical conditions such as cancer and other types of medication can trigger events.
BlackThorn Therapeutics Inc. thinks it has another way. Its drug, called BTRX-246040, started a mid-stage clinical trial in July in adults with the neurobehavioral condition. Patients take the drug once a day for eight weeks. The study is seeking to identify subtypes of major depressive disorder that may be most responsive to BTRX-246040 and similar drugs.
When Diane Legg began seeing black specks in her right eye, she went to an ophthalmologist near her home in Amesbury, Mass. He said she had a torn retina and needed laser surgery.
Legg’s oncologist was skeptical. He was worried that Legg had eye inflammation, called uveitis, that was caused by an immunotherapy drug she had been on for advanced lung cancer. If so, Legg needed to get a far different treatment — and quickly — to avoid vision problems or blindness.
Black and Hispanic kidney transplant patients are less likely than white patients to receive a kidney from a live donor despite concerted efforts over the past two decades to increase organ transplant donation.The incidence rate among white patients who received a live-donor kidney after two years on the waiting list increased four percentage points, climbing to 11% in 2014 from 7% in 1995. At the same time, incidence rates among both black and Hispanic patients decreased, half a percentage point and close to a full percentage point, respectively, according to a study published Tuesday in the Journal of the American Medical Association.
A Menlo Park incubator backed by the American Medical Association has spun out its first company focused on using blockchain to solve data and administrative challenges in the health care business.
San Francisco-based Akiri today is releasing its first product, Akiri Switch, a subscription-based data network for managing health information. It’s a part of the industry’s move to digitize and automate health care using blockchain technology. If successful, blockchain may provide a better way for data to move between payers, providers and patients and result in significant cost reductions.
British neuroscientist Joseph Jebelli first set out to study Alzheimer’s because of his grandfather, who developed the disease when Jebelli was 12.
In the years that followed, Jebelli watched as his grandfather’s memory started to disappear. But Jebelli points out that although a certain amount of memory loss is a natural part of aging, what happened to his grandfather and to other Alzheimer’s patients is different.
“Losing your keys, forgetting where you put your glasses, is completely normal,” he says. ”But when you find your glasses and your keys and you think, ‘What are these for?’ — that’s a sign that there’s something else going on, that it’s not just a memory loss.”
Pat Brady is retiring as CEO of the Roseville hospital he led for nearly two decades.
Brady became chief executive of Sutter Roseville Medical Center in 2000, about three years after it opened to replace the former Roseville Community Hospital. During the last 17 years, Brady oversaw tremendous growth at the hospital, nearly doubling the size of the medical campus.
“I’ve been fortunate to be able to lead an organization that is in the eye of growth,” Brady told the Business Journal.
Jennifer Maher, former CEO of Sutter Davis Hospital, will replace Brady as CEO of Sutter Roseville.